We are live on ! Find out more
VTVT icon

vTv Therapeutics
VTVT

14 hedge funds and large institutions have $798K invested in vTv Therapeutics in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

3.3% more ownership

Funds ownership: 0.11% → 3.41% (+3.3%)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

42% less funds holding

Funds holding: 24 → 14 (-10)

52% less capital invested

Capital invested by funds: $1.65M → $798K (-$848K)

90% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 10

Holders
14
Holders Change
-10
Holders Change %
-41.67%
% of All Funds
0.2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
3
Reduced
4
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
+$15K
2
Morgan Stanley
Morgan Stanley
New York
+$11.9K
3
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$8.16K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$393

Top Sellers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
-$113K
2
State Street
State Street
Massachusetts
-$64.4K
3
Northern Trust
Northern Trust
Illinois
-$24.1K
4
TSS
Two Sigma Securities
New York
-$14.6K
5
SQA
Simon Quick Advisors
New Jersey
-$14.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
SB
1
Samsara BioCapital
California
$470K – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$270K +$393 +28 +0.1%
Morgan Stanley
3
Morgan Stanley
New York
$19.3K +$11.9K +844 +101%
BlackRock
4
BlackRock
New York
$15.4K -$14 -1 -0.1%
TRCT
5
Tower Research Capital (TRC)
New York
$12.3K +$15K +1,070 New
Royal Bank of Canada
6
Royal Bank of Canada
Ontario, Canada
$6K +$8.16K +581 +8,300%
FWM
7
Focused Wealth Management
New York
$2.88K – – –
Osaic Holdings
8
Osaic Holdings
Arizona
$575 -$702 -50 -50%
PA
9
Parallel Advisors
California
$437 – – –
Wells Fargo
10
Wells Fargo
California
$346 -$84 -6 -17%
CPG
11
Cornerstone Planning Group
New Jersey
$219 – – –
SS
12
Sunbelt Securities
Texas
$172 – – –
Bank of America
13
Bank of America
North Carolina
$12 -$112 -8 -89%
JP Morgan Chase
14
JP Morgan Chase
New York
$11 – – –
Geode Capital Management
15
Geode Capital Management
Massachusetts
– -$113K -5,903 Closed
State Street
16
State Street
Massachusetts
– -$64.4K -3,369 Closed
Northern Trust
17
Northern Trust
Illinois
– -$24.1K -1,260 Closed
TSS
18
Two Sigma Securities
New York
– -$14.6K -761 Closed
SQA
19
Simon Quick Advisors
New Jersey
– -$14.3K -750 Closed
Susquehanna International Group
20
Susquehanna International Group
Pennsylvania
– -$9.69K -507 Closed
Millennium Management
21
Millennium Management
New York
– -$5.06K -265 Closed
SFCL
22
Strengthening Families & Communities LLC
Massachusetts
– -$3K -172 Closed
Comerica Bank
23
Comerica Bank
Texas
– -$478 -25 Closed
BNP Paribas Financial Markets
24
BNP Paribas Financial Markets
France
– -$157 -8 Closed
Fidelity Investments
25
Fidelity Investments
Massachusetts
– -$3 – –

VTVT Hedge Fund Activity: Q4 2023 in Review

14 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q4 2023, worth a combined $798K — down 52% from $1.65M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of VTVT and 1 opened new positions — a net loss of 9 holders — while 4 trimmed existing stakes and 3 added.

The largest buyer was Tower Research Capital (TRC), opening a new position worth an estimated $15K. The largest seller was Geode Capital Management, exiting entirely with an estimated $113K sold.

  • 14 institutional investors held vTv Therapeutics (VTVT) as of Q4 2023, down from 24 in Q3 2023.
  • Funds reported $798K of vTv Therapeutics stock for Q4 2023, down 52% quarter-over-quarter.
  • 1 fund opened new vTv Therapeutics positions in Q4 2023 and 10 closed out, a net change of -9 holders.
  • The largest vTv Therapeutics buyer in Q4 2023 was Tower Research Capital (TRC), an estimated $15K added.
  • The largest vTv Therapeutics seller in Q4 2023 was Geode Capital Management, an estimated $113K sold.

Based on aggregated 13F filings for Q4 2023.